| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.54▼ | 1.54▼ | 1.54▼ | 1.59▼ | 1.56▼ |
| MA10 | 1.54▼ | 1.55▼ | 1.56▼ | 1.59▼ | 1.53▼ |
| MA20 | 1.54▼ | 1.57▼ | 1.59▼ | 1.51▲ | 2.01▼ |
| MA50 | 1.56▼ | 1.60▼ | 1.59▼ | 1.53▼ | 2.04▼ |
| MA100 | 1.59▼ | 1.58▼ | 1.54▼ | 2.05▼ | 3.84▼ |
| MA200 | 1.59▼ | 1.49▲ | 1.45▲ | 1.96▼ | 8.86▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | -0.004▼ | -0.010▼ | 0.009▲ | -0.010▼ |
| RSI | 31.500▼ | 37.015▼ | 39.518▼ | 48.386▼ | 43.001▼ |
| STOCH | 30.000 | 15.208▼ | 10.417▼ | 55.375 | 45.352 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -61.404 | -77.341▼ |
| CCI | -211.795▼ | -146.199▼ | -117.600▼ | -52.311 | -18.699 |
|
Thursday, November 20, 2025 10:24 AM
Enrollment in FLASH2 Trial Reaches 50; Interim Analysis in 2Q26 On November 19, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced that enrollment in the FLASH2 trial of HyBryte™ for the treatment of ...
|
|
Thursday, August 21, 2025 01:25 AM
Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA), Evoke Pharma Inc. (NASDAQ:EVOK), KALA BIO Inc. (NASDAQ:KALA), Ginkgo Bioworks Holdings Inc. (NYSE:DNA), and Soligenix Inc ...
|
|
Monday, August 18, 2025 04:54 AM
(RTTNews) - Soligenix (SNGX) announced that the Office of Orphan Products Development of FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for treatment of Behçet ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 16/12/25 | 1.50 | 1.61 | 1.50 | 1.52 | 258,736 |
| 15/12/25 | 1.65 | 1.67 | 1.55 | 1.55 | 208,767 |
| 12/12/25 | 1.63 | 1.695 | 1.5611 | 1.65 | 348,989 |
| 11/12/25 | 1.60 | 1.67 | 1.60 | 1.63 | 362,671 |
| 10/12/25 | 1.62 | 1.65 | 1.545 | 1.60 | 369,505 |
| 09/12/25 | 1.56 | 1.63 | 1.56 | 1.59 | 110,000 |
| 08/12/25 | 1.62 | 1.62 | 1.51 | 1.58 | 404,700 |
| 05/12/25 | 1.64 | 1.67 | 1.495 | 1.61 | 775,022 |
| 04/12/25 | 1.54 | 1.67 | 1.51 | 1.63 | 239,800 |
| 03/12/25 | 1.57 | 1.58 | 1.50 | 1.55 | 202,000 |
|
|
||||
|
|
||||
|
|